Brainstorm

IN8bio, Inc is a leading clinical-stage biopharmaceutical company based in New York, NY, specializing in the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. Their innovative approach employs various techniques, including allogeneic, autologous, iPSC, and genetically modified approaches, to develop novel cell therapies that effectively identify and eradicate tumor cells. With a mission to achieve "CANCER ZERO," IN8bio is at the forefront of gamma-delta T cell research and was the first to bring genetically modified gamma-delta T cells into clinical trials. Their DeltEx platform technologies harness the unique properties of gamma-delta T cells, enabling them to differentiate between healthy and diseased tissue, and contribute to direct tumor cell killing and immune cell activation. With a dedicated team of experts and a robust pipeline of clinical and preclinical assets, IN8bio is committed to advancing next-generation cancer treatments for patients in need.Generated from the website

Solabia USA Inc is a leading company in the cosmetic, nutrition, and pharmaceutical industries, specializing in the production of active ingredients and plant extracts. With a strong focus on innovation and expertise, Solabia offers a wide range of high-quality products and solutions for various applications. As part of the Solabia Group, a global leader in the field, Solabia USA Inc is committed to delivering exceptional products and services, backed by extensive research and development. With a strong presence in the market, Solabia USA Inc continues to drive advancements in the industry, providing customers with cutting-edge solutions and contributing to the success of their businesses.Generated from the website

Protara Therapeutics, Inc. is a biotechnology company based in New York, dedicated to advancing transformative therapies for serious diseases. Its lead investigational cell therapy, TARA-002, aims to treat non-muscle invasive bladder cancer and lymphatic malformations, benefiting from Rare Pediatric Disease Designation from the FDA. In addition to TARA-002, Protara is developing IV Choline Chloride, a phospholipid substrate replacement therapy targeting patients on parenteral support, addressing the significant choline deficiency prevalent in this population. The company is committed to innovative treatments that cater to unmet medical needs in the oncology and pediatric spaces. Generated from the website